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RESUMO – Os autores descrevem o caso de um homem de 84 anos hospitalizado por pneumonia bacteriana que foi posterior-
mente diagnosticado com COVID-19 e observado com exantema flexural. Com terapêutica de suporte o rash desapareceu em 7 
dias e o doente recuperou completamente. Na mesma altura surgiram dois outros casos de infeção por SARS-CoV-2 na mesma 
enfermaria.
O estudo histopatológico e imunopatológico de biópsia de pele mostrou um infiltrado inflamatório perivascular de predomínio 
linfoplasmocitário ligeiro na derme superficial, predominantemente CD4+, um ligeiro epidermotropismo, espongiose e paraque-
ratose focal, compatível com um exantema viral ou uma erupção maculopapular medicamentosa.
Os autores pretendem contribuir para uma melhor compreensão das manifestações da infeção pelo SARS-CoV-2 e alertar para a 
importância da identificação precoce de alterações cutâneas possivelmente associadas a COVID-19. 
PALAVRAS-CHAVE – COVID-19; Exantema; Infecções por Coronavírus; SARS-CoV-2.
A Case of Flexural Exanthema as a Presenting Sign 
for COVID-19 
ABSTRACT – We report a case of a 84-year-old male hospitalized for bacterial pneumonia who, during hospitalization, developed 
a flexural exanthema in parallel with a positive swab for SARS-CoV-2. Supportive therapy was instituted, the rash disappeared in 7 
days and the patient fully recovered. At the same time, two other cases of SARS-CoV-2 infection occurred in the same ward.
Histopathology and immunohistochemistry of a skin biopsy showed a scarce predominantly perivascular lymphocytic infiltration in 
the upper dermis, predominantly by CD4+ T cells, a slight epidermotropism, spongiosis and focal parakeratosis, compatible with a 
viral exanthema or a maculopapular drug eruption. Patch testing with possible culprit drugs were negative.
We seek to add value in understanding all the manifestations of SARS-CoV-2 infection and to draw attention to the importance of 
early identification of skin manifestations in association with COVID-19. 
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INTRODUCTION
The COVID-19 pandemic has had a major worldwide 
impact, even though we still know little about this disea-
se. Along with the typical respiratory symptoms of viral in-
fections, various cutaneous manifestations have also been 
associated with SARS-CoV-2, so Dermatology has made an 
enormous contribution to this pandemic.1 
Two main studies described more than 50% of cuta-
neous manifestations appearing after hospitalization,2,3 
Lesions were mostly a skin rash (>70%) affecting mainly 
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the trunk and upper limbs, which was only mildly pruri-
tic and self-limited (2-5 days duration). But a wide range 
of skin manifestations has been associated with COVID-
19: petechial, erythematous, urticarial, vesicular eruptions, 
transient livedo reticularis, Raynaud phenomena, annular, 
erythema-multiforme and chilblain-like lesions.4-9
Getting to know SARS-CoV-2 manifestations and its pa-
thogenesis is one of the cornerstones of investigation since 
it directs the study of possible treatments. Furthermore, it is 
of utmost importance to raise awareness of COVID-19 skin 
manifestations as primary manifestations.
CASE REPORT
A 84-year-old male was taken to the emergency depart-
ment (ED) as he was found lying on the floor of his home 
with associated sphincter incontinence. His clinical history 
was notable for dyslipidemia, hypertension and an ischemic 
stroke. Since 2016, he had thrombocytopenia of unknown 
cause. He was under daily treatment with amlodipine 5 mg, 
furosemide 80 mg, and simvastatin 20 mg. No drug aller-
gies were reported.
At the ED, he had a 7-point Glasgow Coma Scale, was 
hypothermic (tympanic temperature 29.9ºC) and had pu-
rulent respiratory secretions which needed to be aspirated. 
There were no acute findings on brain computed tomo-
graphy (CT) scan or electroencephalogram. He had leu-
cocytosis (14.2 x 109/L) with neutrophilia (12.72 x 109/L), 
lymphocytopenia (0.47 x 109/L), thrombocytopenia (104 
x 109/L), high C-reactive protein (4.43 mg/dL) and D-di-
mers (671 ng/dL). A chest radiography showed bilateral 
hilar reinforcement and areas of hypotransparency alrea-
dy present in previous exams. Chest CT showed bilateral 
thickening of the bronchial walls, an area of parenchymal 
densification in the apical segment of the right upper lobe, 
and fibro-atelectatic areas in the lower lobes. A nasopha-
ryngeal swab for SARS-CoV-2 was negative. He was then 
admitted to a medical ward with the diagnosis of commu-
nity-acquired pneumonia and hypoxemic respiratory insu-
fficiency.
The patient completed 5 days of azithromycin 500 mg 
IV and 8 days of ceftriaxone 1000 mg IV with recovery of 
consciousness, resolution of respiratory failure and norma-
lization of imaging and analytical parameters, except for 
thrombocytopenia. 
Nevertheless, on day 7 of hospitalization, with no as-
sociated respiratory distress or other relevant systemic 
symptoms, he developed a non-pruritic symmetric maculo-
papular rash on the trunk and arms, next to axillary folds, 
with red confluent erythematous lesions that extended to 
the shoulder and flexures. On the following day, cutaneous 
lesions progressed to the cervical region and upper trunk 
(Fig. 1), subsequently stabilizing until resolution within 7 
days of onset. Lower limbs, face, palmoplantar regions and 
mucous membranes were spared. Concomitantly, a second 
SARS-CoV-2 nasopharyngeal swab was positive and there 
was a slight increase of inflammatory serum parameters, 
namely leukocytes (10.4 x 109/L), neutrophils (7.95 x 109/L) 
and C-reactive protein (7.47 mg/dL), but prothrombin time, 
activated partial thromboplastin, renal, hepatic and thyroid 
function tests, antinuclear (ANA) and anti-neutrophil cyto-
plasmic antibodies (ANCA) were normal or negative. Two 
other patients in the same ward, with no exposure to anti-
biotics, had a similar rash and has a positive nasopharyn-
geal swab for SARS-CoV-2.
For the differential diagnosis of this patient a non-im-
mediate drug eruption related to the antibiotics and a viral 
exanthema related with SARS-CoV-2 infection were consi-
dered. A punch biopsy performed on the patient’s right arm 
showed mild parakeratosis, focal spongiosis and lympho-
cyte exocytosis. Vasodilation was seen in the upper dermis 
with a predominantly perivascular lymphocytic infiltrate, 
no eosinophils and very rare extravasated red blood cells. 
There were no signs of vasculitis (Fig. 2). Immunohistoche-
mistry revealed almost exclusively T cells, predominantly 
CD4+, with only mild expression of CD8+.
The rash resolved in a week with no specific treatment 
and the patient recovered fully from COVID-19 only with 
supportive therapy. Six weeks after recovery, a patch test 
with several systemic antibiotics, including azithromycin 
and ceftriaxone at 10% pet (Chemotechnique Diagnostics, 
Vellinge Sweden), performed according to the ESCD recom-
mendations,10 was negative on day 2 and day 4.
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Figure 1 - Maculopapular rash in the right axillary region.  
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DISCUSSION
A symmetric maculopapular rash of the neck, trunk 
and upper limbs, occasionally also with a flexural distri-
bution, that appears concomitantly with the identification 
of SARS-CoV-2 in the nasopharyngeal mucosae has been 
described by other authors11 and may be the initial mani-
festation of the viral infection. However, in this case, we 
cannot absolutely exclude the pathogenic role of the an-
tibiotics taken for bacterial pneumonia, even though ne-
gative patch tests and the scarcity of eosinophils in the 
skin biopsy make it unlikely. Otherwise, as reported for 
Epstein-Barr virus and cytomegalovirus, the simultaneous 
viral infection and antibiotic intake may have enhanced 
the cutaneous rash.
Pathophysiology of these cutaneous lesions in COVID-
19 is still unknown. A skin biopsy showing vasodilation 
and a perivascular infiltrate of CD4+ T cells in the upper 
dermis with a slight epidermotropism has been shown in 
other viral exanthema and is similar to the ones found in 
other skin biopsies from COVID-19 patients.6,12 
SARS-CoV-2 has been widely suspected as the ae-
tiology of different cutaneous manifestations in infected 
patients, with maculopapular and urticarial exanthema 
mostly associated with an indolent course with minimal 
or even absent fever or respiratory symptoms. However, 
patients and health professionals are not fully aware that 
exanthema may be an initial manifestation of the infec-
tion, and that these patients are likely contagious.
In summary, maculopapular exanthema has been des-
cribed in patients who tested positive for SARS-CoV-2, 
but more studies are needed to clear the pathomecha-
nisms involved in exanthema from this virus. Exanthema 
should raise an early suspicion for this infection and the 
awareness of the medical staff may contribute for an early 
diagnosis and prevention of transmission.
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